<DOC>
	<DOCNO>NCT00925730</DOCNO>
	<brief_summary>This study access degree pimecrolimus absorb pimecrolimus cream 1 % blood apply repeatedly occlusion ( i.e . area treat wrap plastic film ) 8 day patient moderate severe atopic eczema .</brief_summary>
	<brief_title>Open-label Study Investigate Systemic Exposure Adult Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1 % Under Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients 2 18 year age Patients diagnosis moderate severe atopic dermatitis , assess score â‰¥ 3 Investigator 's Global Assessment . AD involve least 30 % body surface area determine rule nine Lund Browder chart . Erythrodermic patient Netherton 's syndrome Patients know serious adverse reaction hypersensitivity excipients study medication Patients history cancer , skin malignancy lymphoproliferative disorder immunocompromise , include positive HIV ( ELISA Western blot ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>AD</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>blood</keyword>
	<keyword>absorption</keyword>
	<keyword>systemic</keyword>
</DOC>